Zobrazit více v PubMed
Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10:1054–1072. doi: 10.1101/gad.10.9.1054.
PubMed
DOI
Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331. doi: 10.1016/S0092-8674(00)81871-1.
PubMed
DOI
Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 1993;12:461–468.
PubMed
PMC
Wu X., Bayle J.H., Olson D., Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7:1126–1132. doi: 10.1101/gad.7.7a.1126.
PubMed
DOI
Lane D.P. Cancer. p53, guardian of the genome. Nature. 1992;358:15–16. doi: 10.1038/358015a0.
PubMed
DOI
Saito S., Goodarzi A.A., Higashimoto Y., Noda Y., Lees-Miller S.P., Appella E., Anderson C.W. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J. Biol. Chem. 2002;277:12491–12494. doi: 10.1074/jbc.C200093200.
PubMed
DOI
Siliciano J.D., Canman C.E., Taya Y., Sakaguchi K., Appella E., Kastan M.B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 1997;11:3471–3481. doi: 10.1101/gad.11.24.3471.
PubMed
DOI
PMC
Bartek J., Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421–429. doi: 10.1016/S1535-6108(03)00110-7.
PubMed
DOI
Fedier A., Schlamminger M., Schwarz V.A., Haller U., Howell S.B., Fink D. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann. Oncol. 2003;14:938–945. doi: 10.1093/annonc/mdg240.
PubMed
DOI
Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci. 2006;31:402–410. doi: 10.1016/j.tibs.2006.05.004.
PubMed
DOI
Canman C.E., Wolff A.C., Chen C.Y., Fornace A.J., Jr., Kastan M.B. The p53-dependent G1 cell cycle checkpoint pathway and ataxiatelangiectasia. Cancer Res. 1994;54:5054–5058.
PubMed
Canman C.E., Lim D.S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M.B., Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 1998;281:1677–1679. doi: 10.1126/science.281.5383.1677.
PubMed
DOI
Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998;281:1674–1677. doi: 10.1126/science.281.5383.1674.
PubMed
DOI
Hirao A., Kong Y.Y., Matsuoka S., Wakeham A., Ruland J., Yoshida H., Liu D., Elledge S.J., Mak T.W. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 2000;287:1824–1827. doi: 10.1126/science.287.5459.1824.
PubMed
DOI
Lin W.C., Lin F.T., Nevins J.R. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 2001;15:1833–1844.
PubMed
PMC
Muller P., Ceskova P., Vojtesek B. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy. J. Biol. Chem. 2005;280:6682–6691. doi: 10.1074/jbc.M412767200.
PubMed
DOI
Vojtesek B., Bartek J., Midgley C.A., Lane D.P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods. 1992;151:237–244. doi: 10.1016/0022-1759(92)90122-A.
PubMed
DOI
Blaydes J.P., Hupp T.R. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene. 1998;17:1045–1052. doi: 10.1038/sj.onc.1202014.
PubMed
DOI
Chen J., Marechal V., Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 1993;13:4107–4114.
PubMed
PMC
Sheard M.A., Krammer P.H., Zaloudik J. Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95. Br. J. Cancer. 1999;80:1689–1696. doi: 10.1038/sj.bjc.6690585.
PubMed
DOI
PMC
Sheard M.A., Vojtesek B., Janakova L., Kovarik J., Zaloudik J. Upregulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int. J. Cancer. 1997;73:757–762. doi: 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1.
PubMed
DOI
Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005;4:307–320. doi: 10.1038/nrd1691.
PubMed
DOI
Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–7279. doi: 10.1038/sj.onc.1206933.
PubMed
DOI
Kurz E.U., Douglas P., Lees-Miller S.P. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J. Biol. Chem. 2004;279:53272–53281. doi: 10.1074/jbc.M406879200.
PubMed
DOI
McHugh P.J., Spanswick V.J., Hartley J.A. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2001;2:483–490. doi: 10.1016/S1470-2045(01)00454-5.
PubMed
DOI
Kartalou M., Essigmann J.M. Recognition of cisplatin adducts by cellular proteins. Mutat. Res. 2001;478:1–21.
PubMed
Chaney S.G., Campbell S.L., Bassett E., Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev. Oncol. Hematol. 2005;53:3–11. doi: 10.1016/j.critrevonc.2004.08.008.
PubMed
DOI
Dronkert M.L., Kanaar R. Repair of DNA interstrand cross-links. Mutat. Res. 2001;486:217–247.
PubMed
Damia G., Filiberti L., Vikhanskaya F., Carrassa L., Taya Y., D’Incalci M., Broggini M. Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia. 2001;3:10–16. doi: 10.1038/sj.neo.7900122.
PubMed
DOI
PMC
Khanna K.K., Keating K.E., Kozlov S., Scott S., Gatei M., Hobson K., Taya Y., Gabrielli B., Chan D., Lees-Miller S.P., Lavin M.F. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat. Genet. 1998;20:398–400. doi: 10.1038/3882.
PubMed
DOI
Lakin N.D., Hann B.C., Jackson S.P. The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53. Oncogene. 1999;18:3989–3995. doi: 10.1038/sj.onc.1202973.
PubMed
DOI
Tibbetts R.S., Brumbaugh K.M., Williams J.M., Sarkaria J.N., Cliby W.A., Shieh S.Y., Taya Y., Prives C., Abraham R.T. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 1999;13:152–157. doi: 10.1101/gad.13.2.152.
PubMed
DOI
PMC
Chehab N.H., Malikzay A., Appel M., Halazonetis T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 2000;14:278–288.
PubMed
PMC
Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 1999;96:13777–13782. doi: 10.1073/pnas.96.24.13777.
PubMed
DOI
PMC
Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91:325–334. doi: 10.1016/S0092-8674(00)80416-X.
PubMed
DOI
Delia D., Fontanella E., Ferrario C., Chessa L., Mizutani S. DNA damage-induced cell-cycle phase regulation of p53 and p21waf1 in normal and ATM-defective cells. Oncogene. 2003;22:7866–7869. doi: 10.1038/sj.onc.1207086.
PubMed
DOI
Hill R., Bodzak E., Blough M.D., Lee P.W. p53 Binding to the p21 promoter is dependent on the nature of DNA damage. Cell Cycle. 2008;7:2535–2543.
PubMed
Noda A., Ning Y., Venable S.F., Pereira-Smith O.M., Smith J.R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 1994;211:90–98. doi: 10.1006/excr.1994.1063.
PubMed
DOI
Lu Y., Tatsuka M., Takebe H., Yagi T. Involvement of cyclin-dependent kinases in doxorubicin-induced apoptosis in human tumor cells. Mol. Carcinog. 2000;29:1–7. doi: 10.1002/1098-2744(200009)29:1<1::AID-MC1>3.0.CO;2-A.
PubMed
DOI
Lu Y., Yamagishi N., Yagi T., Takebe H. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. Oncogene. 1998;16:705–712. doi: 10.1038/sj.onc.1201585.
PubMed
DOI
Luo Y., Hurwitz J., Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature. 1995;375:159–161. doi: 10.1038/375159a0.
PubMed
DOI
Tang J.J., Shen C., Lu Y.J. Requirement for pre-existing of p21 to prevent doxorubicin-induced apoptosis through inhibition of caspase-3 activation. Mol. Cell Biochem. 2006;291:139–144. doi: 10.1007/s11010-006-9206-7.
PubMed
DOI
Crescenzi E., Palumbo G., de Boer J., Brady H.J. Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy. Clin. Cancer Res. 2008;14:1877–1887. doi: 10.1158/1078-0432.CCR-07-4298.
PubMed
DOI